1 / 6

Hospital Acquired Disease Testing Market to Register a CAGR of 19.9% 2015-2023 due to High Prevalence of HAIs

The global hospital acquired disease testing market was valued at US$0.4 bn in 2014 and is expected to grow at a CAGR of 19.9% from 2015 to 2023, to reach an estimated value of US$2.0 bn by 2023.

kksingha
Télécharger la présentation

Hospital Acquired Disease Testing Market to Register a CAGR of 19.9% 2015-2023 due to High Prevalence of HAIs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 Published Date 24-Dec-2015 85 Page Report Request Sample Buy Now Press Release Global Hospital Acquired Disease Testing Market to Register a CAGR of 19.9% 2015-2023 due to High Prevalence of HAIs Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Hospital Acquired Disease Testing Market REPORT DESCRIPTION Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 The research report includes an evaluation of the diagnostic tests performed to diagnose hospital-related infections. Also known as nosocomial infections, hospital acquired diseases have become a growing cause of morbidity across the world. The research report has used SWOT analysis to identify the strengths, weaknesses, opportunities, and threats of the market. Furthermore, it also includes Porter’s five forces analysis that highlights the threat of new entrants, the threat of substitute products or services, the bargaining power of customers (buyers), the bargaining power of suppliers, and the intensity of competitive rivalry. Request For Report Brochure :- http://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=12791 According to the research report, the global hospital acquired disease testing market was valued at US$0.4 bn in 2014 and is likely to reach US$2.0 bn by 2023, rising at a CAGR of 19.9% from 2015 to 2023. This growth will be attributable to the growing number of cases of nosocomial infections. In the past few years, the high incidence of nosocomial infections has led to a high rate of morbidity. This is especially seen amongst patients who have a weaker immune system and fall prey to poor hygiene conditions in the hospitals. The growing pool of geriatrics is the primary reasons for the growth in the prevalence of hospital acquired diseases across the globe. The global hospital acquired disease testing market has been segmented on the basis of test and geography. On the basis of test, this market is segmented into urinary tract infections, pneumonia infections, bloodstream-associated infections, MRSA infections, surgical site infections, and others. Geographically, this market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Of all the segments based on test type, the hospital acquired urinary tract infection diagnostics segment holds a dominating share in the overall market due to the high prevalence of urinary infections and its impact on morbidity. Analysts predict that this segment will continue to show its dominance in the market through 2023. Additionally, the market for testing solutions such as surgical site infections and pneumonia (ventilator associated and hospital associated infections) will also expand due to the high prevalence of these conditions in emerging economies in Latin America, Asia Pacific, and other developing regions. 2 Transparency Market Research

  3. Hospital Acquired Disease Testing Market Some of the top players mentioned in the research report about the global hospital acquired disease testing market are Diatherix Laboratories Inc., Qiagen GmbH, Gen-Probe Inc., L Hoffman La Roche, Cepheid, Inc., Meridian Biosciences, Life Technologies Corporation, Nordion, Inc., and Cantel Medical Corporation. The research report also offers a detailed explanation of the competitive landscape of the global hospital acquired disease testing market. Furthermore, it also assesses the financial overview, research and development activities, business and marketing strategies, product portfolio, and strategic mergers and acquisitions of these top players in the overall market. Browse Full Report With TOC:- http://www.transparencymarketresearch.com/neurorehabilitation-devices- market.html Table of Contents:- Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology Chapter 2 Executive Summary 2.1 Global Hospital Acquired Disease Testing Market Share, by Geography, 2014–2023 (US$ Mn) 2.2 Global Hospital Acquired Disease Testing Market, by Test, 2014 (US$ Mn) 2.3 Hospital Acquired Disease Testing Market Snapshot Chapter 3 Hospital Acquired Disease Testing Market – Industry Analysis 3.1 Introduction 3.2 Market Drivers 3.2.1 Establishment of government guidelines and code for prevention of HAIs 3.2.2 Increase in prevalence of HAIs and rise in the number of drug resistant pathogens 3.3 Restraints 3.3.1 Stringent regulations and guidance framework 3 Transparency Market Research

  4. Hospital Acquired Disease Testing Market 3.3.2 Lack of controlling authorities and control programs in less developed regions 3.4 Opportunity 3.4.1 Passage of the Patient Care and Affordable Care Act in the U.S. 3.4.2 Technological development in the field of molecular diagnostics 3.5 Porter’s Five Forces Analysis 3.6 Market Attractiveness Analysis– Hospital Acquired Disease Testing Market, by Geography (2014) (Value %) Chapter 4 Market Segmentation – By Test 4.1 Introduction 4.2 Global Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn) 4.2.1 Global Urinary Tract Infection Testing Market Revenue, 2013–2023 (US$ Mn) 4.2.2 Global Surgical Site Infection Testing Market Revenue, 2013–2023 (US$ Mn) 4.2.3 Global Pneumonia Infection Testing Market Revenue, 2013–2023 (US$ Mn) 4.2.4 Global Bloodstream Infection Testing Market Revenue, 2013–2023 (US$ Mn) 4.2.5 Global Others Infection Testing Market Revenue, 2013–2023 (US$ Mn) Chapter 5 Market Segmentation – By Geography 5.1 Introduction 5.2 Global Hospital Acquired Disease Testing Market Revenue, by Geography, 2013–2023 (US$ Mn) 5.3 North America Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn) 5.4 North America Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn) 5.5 Europe Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn) 5.6 Europe Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn) 5.7 Asia Pacific Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn) 5.8 Asia Pacific Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn) 5.9 Latin America Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn) 5.10 Latin America Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn) 5.11 Middle East & Africa Hospital Acquired Disease Testing Market Revenue, by Country, 2013–2023 (US$ Mn) 4 Transparency Market Research

  5. Hospital Acquired Disease Testing Market 5.12 Middle East & Africa Hospital Acquired Disease Testing Market Revenue, by Test, 2013–2023 (US$ Mn) Chapter 6 Recommendations Chapter 7 Company Profiles 7.1 Abbott Laboratories 7.2 Alere, Inc. 7.3 Becton, Dickinson and Company 7.4 bioMérieux SA 7.5 F. Hoffmann-La Roche Ltd. 7.6 Hologic, Inc. 7.7 QIAGEN 7.8 Siemens Healthcare 7.9 Diatherix Laboratories, Inc. 7.10 Meridian Bioscience, Inc. 7.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation) 7.12 Cepheid, Inc. About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact Transparency Market Research 5 Transparency Market Research

  6. Hospital Acquired Disease Testing Market 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ 6 Transparency Market Research

More Related